1. Immunology/Inflammation NF-κB
  2. COX NF-κB
  3. Hederagenin

Hederagenin is a triterpenoid saponin with orally active and antitumor activity. Hederagenin can inhibit the expression of iNOS, COX-2, and NF-κB in cells induced by LPS stimulation. Hederagenin also increases ROS production in cancer cells, disrupts mitochondrial membrane potential, and induces apoptosis. Hederagenin also sensitizes cancer cells to Cisplatin (HY-17394) and Paclitaxel (HY-B0015), enhancing induced apoptosis. Hederagenin also has preventive potential against alcoholic liver injury.

For research use only. We do not sell to patients.

Hederagenin Chemical Structure

Hederagenin Chemical Structure

CAS No. : 465-99-6

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 44 In-stock
Solution
10 mM * 1 mL in DMSO USD 44 In-stock
Solid
5 mg USD 40 In-stock
10 mg USD 60 In-stock
25 mg USD 100 In-stock
50 mg USD 150 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Hederagenin:

Top Publications Citing Use of Products

View All COX Isoform Specific Products:

View All NF-κB Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Hederagenin is a triterpenoid saponin with orally active and antitumor activity. Hederagenin can inhibit the expression of iNOS, COX-2, and NF-κB in cells induced by LPS stimulation. Hederagenin also increases ROS production in cancer cells, disrupts mitochondrial membrane potential, and induces apoptosis. Hederagenin also sensitizes cancer cells to Cisplatin (HY-17394) and Paclitaxel (HY-B0015), enhancing induced apoptosis. Hederagenin also has preventive potential against alcoholic liver injury[1][2][3][4][5][6].

Cellular Effect
Cell Line Type Value Description References
518A2 EC50
> 30 μM
Compound: He; Hederagenin
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
[PMID: 27017553]
518A2 EC50
34.9 μM
Compound: He
Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by sulforhodamine B assay
[PMID: 26476750]
8505C EC50
> 30 μM
Compound: He; Hederagenin
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
[PMID: 27017553]
8505C EC50
38 μM
Compound: He
Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by sulforhodamine B assay
[PMID: 26476750]
A2780 EC50
> 30 μM
Compound: He
Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay
[PMID: 30840925]
A2780 EC50
> 30 μM
Compound: He; Hederagenin
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
[PMID: 27017553]
A2780 EC50
> 60 μM
Compound: He
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
[PMID: 29024910]
A2780 EC50
19.9 μM
Compound: He
Cytotoxicity against human A2780 cells assessed as cell survival after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A2780 cells assessed as cell survival after 96 hrs by sulforhodamine B assay
[PMID: 26476750]
A-375 EC50
> 60 μM
Compound: He
Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
[PMID: 29024910]
A549 IC50
> 10 μM
Compound: Hederagenin
Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay
Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay
[PMID: 31718182]
A549 IC50
> 10 μM
Compound: Hederagenin
Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
[PMID: 29131631]
A549 IC50
> 100 μM
Compound: alpha-hederagenin
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
[PMID: 29040953]
A549 IC50
> 200 μM
Compound: 3
Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence
Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence
[PMID: 19200744]
A549 EC50
> 30 μM
Compound: He; Hederagenin
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
[PMID: 27017553]
A549 IC50
10.249 μM
Compound: Hederagenin
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 28237662]
A549 EC50
29 μM
Compound: He
Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by sulforhodamine B assay
[PMID: 26476750]
A549 IC50
38.64 μM
Compound: HE
Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
[PMID: 23992864]
A549 IC50
39 μM
Compound: 3
Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test
Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test
[PMID: 19200744]
AGS IC50
36.14 μM
Compound: alpha-hederagenin
Antiproliferative activity against human AGS cells after 72 hrs by MTT assay
Antiproliferative activity against human AGS cells after 72 hrs by MTT assay
[PMID: 29040953]
BC IC50
> 5 μg/mL
Compound: Hederagenin
Cytotoxicity against human BC cells by colorimetric method
Cytotoxicity against human BC cells by colorimetric method
[PMID: 16038539]
BGC-823 IC50
52.07 μM
Compound: alpha-hederagenin
Antiproliferative activity against human BGC823 cells after 72 hrs by MTT assay
Antiproliferative activity against human BGC823 cells after 72 hrs by MTT assay
[PMID: 29040953]
DLD-1 IC50
> 100 μM
Compound: 3
Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test
Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test
[PMID: 19200744]
DLD-1 IC50
> 200 μM
Compound: 3
Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence
Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence
[PMID: 19200744]
FaDu EC50
> 30 μM
Compound: He
Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay
Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay
[PMID: 30840925]
FaDu EC50
> 60 μM
Compound: He
Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
[PMID: 29024910]
HeLa IC50
42.27 μM
Compound: HE
Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
[PMID: 23992864]
HeLa IC50
53.96 μM
Compound: alpha-hederagenin
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
[PMID: 29040953]
HepG2 CC50
> 1000 μM
Compound: He
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
[PMID: 29024910]
HepG2 IC50
> 20 μM
Compound: 15
Inhibition of TNF-alpha-induced NFkappaB activation in human HepG2 cells after 1 hr by luciferase reporter assay
Inhibition of TNF-alpha-induced NFkappaB activation in human HepG2 cells after 1 hr by luciferase reporter assay
[PMID: 21870831]
HepG2 IC50
28.05 μM
Compound: HE
Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
[PMID: 23992864]
HL-60 IC50
27.52 μM
Compound: HE
Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay
[PMID: 23992864]
HT-29 EC50
> 30 μM
Compound: He
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay
[PMID: 30840925]
HT-29 EC50
> 30 μM
Compound: He; Hederagenin
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
[PMID: 27017553]
HT-29 EC50
> 60 μM
Compound: He
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
[PMID: 29024910]
HT-29 EC50
50 μM
Compound: He
Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by sulforhodamine B assay
Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by sulforhodamine B assay
[PMID: 26476750]
KB IC50
> 10 μM
Compound: Hederagenin
Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay
Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay
[PMID: 31718182]
KB IC50
> 10 μM
Compound: Hederagenin
Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
[PMID: 29131631]
KB IC50
> 5 μg/mL
Compound: Hederagenin
Cytotoxicity against human KB cells by colorimetric method
Cytotoxicity against human KB cells by colorimetric method
[PMID: 16038539]
KB IC50
14.631 μM
Compound: Hederagenin
Cytotoxicity against human KB cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human KB cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 28237662]
KB IC50
54.43 μM
Compound: alpha-hederagenin
Antiproliferative activity against human KB cells after 72 hrs by MTT assay
Antiproliferative activity against human KB cells after 72 hrs by MTT assay
[PMID: 29040953]
M14 IC50
58 μM
Compound: 6
Cytotoxicity against human M14 cells after 48 hrs by MTT assay
Cytotoxicity against human M14 cells after 48 hrs by MTT assay
[PMID: 21954959]
MCF7 IC50
> 10 μM
Compound: Hederagenin
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay
[PMID: 31718182]
MCF7 IC50
> 10 μM
Compound: Hederagenin
Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
[PMID: 29131631]
MCF7 EC50
> 30 μM
Compound: He
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay
[PMID: 30840925]
MCF7 EC50
> 30 μM
Compound: He; Hederagenin
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
[PMID: 27017553]
MCF7 EC50
25.7 μM
Compound: He
Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by sulforhodamine B assay
[PMID: 26476750]
MCF7 IC50
39.389 μM
Compound: Hederagenin
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 28237662]
MDA-MB-231 IC50
> 10 μM
Compound: Hederagenin
Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay
[PMID: 31718182]
MDA-MB-231 IC50
> 10 μM
Compound: Hederagenin
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay
[PMID: 29131631]
MDA-MB-231 IC50
36.609 μM
Compound: Hederagenin
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 28237662]
MKN-45 IC50
53.69 μM
Compound: alpha-hederagenin
Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay
Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay
[PMID: 29040953]
NCI-H187 IC50
> 5 μg/mL
Compound: Hederagenin
Cytotoxicity against human NCI-H187 cells by colorimetric method
Cytotoxicity against human NCI-H187 cells by colorimetric method
[PMID: 16038539]
NCI-H1975 IC50
> 10 μM
Compound: Hederagenin
Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay
Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay
[PMID: 31718182]
NCI-H1975 IC50
> 10 μM
Compound: Hederagenin
Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay
Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay
[PMID: 31718182]
NIH3T3 EC50
> 30 μM
Compound: He
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay
[PMID: 30840925]
NIH3T3 EC50
> 30 μM
Compound: He; Hederagenin
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
[PMID: 27017553]
Sf9 IC50
> 20 μM
Compound: Hederagenin
Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay
Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay
[PMID: 31718182]
Sf9 IC50
> 20 μM
Compound: Hederagenin
Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k
Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k
[PMID: 31718182]
Sf9 IC50
> 20 μM
Compound: Hederagenin
Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki
Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki
[PMID: 31718182]
SW-1736 EC50
> 30 μM
Compound: He
Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay
Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay
[PMID: 30840925]
SW-1736 EC50
> 60 μM
Compound: He
Cytotoxicity against human SW1736 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
Cytotoxicity against human SW1736 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
[PMID: 29024910]
U-87MG ATCC IC50
35.95 μM
Compound: HE
Cytotoxicity against human U87MG cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human U87MG cells assessed as cell viability after 72 hrs by MTT assay
[PMID: 23992864]
In Vitro

Hederagenin (1 μM, 2 μM; 48 h) disrupts mitochondrial membrane potential, increases intracellular reactive oxygen species (ROS) content, and has a cytotoxic effect on cancer cells[4].
Hederagenin (1 μM, 2 μM; 48 h) induces apoptosis in human colon cancer LoVo cells, upregulates apoptosis-related proteins (Bax), and reduces apoptosis inhibitory proteins (Bcl-2, Bcl-xL, and Survivin) levels[4].
Hederagenin (50 μM; 4 h) also blocks autophagic flux-induced ROS accumulation and enhances the cytotoxicity of Cisplatin and Paclitaxel in lung cancer cells[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Hederagenin (25 mg/kg; po; 11 d) alone did not affect tumor growth in NCI-H1299 xenograft mice. However, it has a synergistic effect with Cisplatin (1 mg/kg) to inhibit tumor growth[4].
Hederagenin (50 mg/kg; po; once daily for 21 days) exerts anti-inflammatory and anti-apoptotic activities and reduces liver damage induced by 25% ethanol in mice[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

472.70

Formula

C30H48O4

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

CC1(C)CC[C@@](CC[C@]2(C)C3=CC[C@@]4([H])[C@@]2(C)CC[C@]5([H])[C@]4(C)CC[C@H](O)[C@]5(CO)C)(C(O)=O)[C@@]3([H])C1

Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (105.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1155 mL 10.5775 mL 21.1551 mL
5 mM 0.4231 mL 2.1155 mL 4.2310 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (5.29 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (5.29 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.95%

References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.1155 mL 10.5775 mL 21.1551 mL 52.8877 mL
5 mM 0.4231 mL 2.1155 mL 4.2310 mL 10.5775 mL
10 mM 0.2116 mL 1.0578 mL 2.1155 mL 5.2888 mL
15 mM 0.1410 mL 0.7052 mL 1.4103 mL 3.5258 mL
20 mM 0.1058 mL 0.5289 mL 1.0578 mL 2.6444 mL
25 mM 0.0846 mL 0.4231 mL 0.8462 mL 2.1155 mL
30 mM 0.0705 mL 0.3526 mL 0.7052 mL 1.7629 mL
40 mM 0.0529 mL 0.2644 mL 0.5289 mL 1.3222 mL
50 mM 0.0423 mL 0.2116 mL 0.4231 mL 1.0578 mL
60 mM 0.0353 mL 0.1763 mL 0.3526 mL 0.8815 mL
80 mM 0.0264 mL 0.1322 mL 0.2644 mL 0.6611 mL
100 mM 0.0212 mL 0.1058 mL 0.2116 mL 0.5289 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Hederagenin
Cat. No.:
HY-N0256
Quantity:
MCE Japan Authorized Agent: